Carbonbio's website does not provide details about its product or service.

Carisma Therapeutics develops chimeric antigen receptor macrophages (CAR-Macrophages) to target solid tumors by engineering a patient's own immune cells to enhance tumor infiltration and activate anti-tumor immunity. This approach addresses the challenges of immunosuppressive tumor microenvironments and antigen heterogeneity, offering a potential long-term treatment strategy for cancer patients.

Cerevance utilizes its proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform to identify novel therapeutic targets for neurological diseases, including Parkinson's and Alzheimer's. The company develops cell type-specific therapies aimed at addressing the unmet medical needs associated with neurodegenerative and psychiatric disorders.

Drive Therapeutics is developing targeted gene therapies to treat retinal diseases, focusing on restoring vision by addressing the underlying genetic causes. The company aims to improve patient outcomes by providing precise, long-lasting treatments that reduce the progression of vision loss.

Entrada Therapeutics develops intracellular therapeutics using its proprietary EEV™ Platform to target previously inaccessible disease-causing mechanisms within cells. The company focuses on treating devastating diseases by creating potential therapies that span from discovery to clinical stages across various therapeutic areas.

Flare Therapeutics utilizes a novel approach to target switch sites on transcription factors, enabling the development of small molecule medicines that can precisely modulate gene expression. The company focuses on creating therapies for precision oncology by addressing the challenges of drugging previously inaccessible transcription factors.

Freenome provides a blood‑based early cancer detection platform that uses multiomics profiling—integrating genomics, epigenomics, proteomics, and metabolomics—with AI‑driven analysis to identify cancer at its most treatable stages. The minimally invasive test is designed for routine screening across multiple cancer types and is validated through ongoing clinical programs for use by healthcare providers.

The startup develops immuno-modulatory antibodies targeting cancer and immune-related diseases, focusing on immuno-oncology therapies for solid tumors such as breast, gastric, and ovarian cancers. Their antibodies address significant unmet medical needs by enhancing the immune response against malignant cells.

Immunitas Therapeutics utilizes single-cell genomics to develop targeted antibody-based therapies for cancer and autoimmune diseases, focusing on the CD161-CLEC2D pathway. Their lead candidate, IMT-009, is currently in clinical trials for treating refractory tumors, addressing the need for effective treatments in patients with limited options.

Metagenomi utilizes metagenomics and machine learning to discover and develop novel genome editing systems that enable precise modifications to the human genome. This technology addresses the limitations of existing gene editing methods by providing a versatile toolbox capable of targeting specific sites for therapeutic interventions.

Onfly provides a travel and expense management platform that enables corporate users to book travel in under three minutes while automating expense reporting and reconciliation processes. The solution enhances financial transparency and reduces errors and fraud, allowing companies to optimize their travel expenditures and improve overall efficiency.

Orchard Therapeutics develops hematopoietic stem cell (HSC) gene therapies to treat severe genetic diseases, such as metachromatic leukodystrophy. Their platform aims to provide long-term therapeutic benefits by addressing the underlying genetic causes of these conditions.

Palvella Therapeutics develops the QTORIN™ platform, a patented topical drug delivery system designed to achieve therapeutic concentrations in the deep layers of the skin for treating rare genetic dermatological diseases. The company addresses the lack of FDA-approved therapies for these conditions, aiming to provide effective treatment options for patients suffering from mTOR-driven skin disorders.

Pliant Therapeutics is developing selective small molecule integrin inhibitors to target the molecular drivers of fibrotic diseases, including idiopathic pulmonary fibrosis. Their approach aims to provide safer and more effective treatment options for patients suffering from these debilitating conditions.

Pyxis Oncology develops antibody-drug conjugates (ADCs) and monoclonal antibody immunotherapies to enhance the immune response against difficult-to-treat cancers. Their targeted therapeutics aim to improve patient outcomes by delivering potent agents directly to tumor cells and activating the immune system to combat cancer's defense mechanisms.

Science is a clinical-stage technology company developing biohybrid neural interfaces and advanced neural recording electronics to address serious unmet medical needs in neuroscience. Their technologies aim to enhance neural communication and restore vision, facilitating new treatment possibilities for patients with neurological disorders.

Skyhawk Therapeutics develops small molecule therapeutics that modify RNA expression to target diseases such as Huntington's Disease, with its lead candidate, SKY-0515, demonstrating a 72% reduction in HTT mRNA during clinical trials. The company's proprietary SKYSTAR® platform accelerates the creation of RNA-targeting drugs across neurology, oncology, and fibrotic diseases, addressing significant unmet medical needs.

Star Therapeutics develops best-in-class antibody therapies targeting serious diseases, with a focus on von Willebrand disease and other bleeding disorders. Their pipeline-in-a-product strategy utilizes novel biology to create effective treatments that meet the real-world needs of patients.

Vittoria Biotherapeutics utilizes its proprietary Senza5 platform to develop next-generation autologous CAR T-cell therapies that enhance efficacy and safety while reducing manufacturing time to five days. The company targets the challenges of low potency and accessibility in current immunotherapy treatments for oncology and immunology.

Zenas BioPharma is developing Obexelimab, a bifunctional monoclonal antibody that targets CD19 and FcγRIIb to suppress B cell activity, which is a key factor in autoimmune diseases. The company aims to provide effective therapies for patients suffering from these conditions, addressing significant unmet medical needs in immunology.